Bidding war?, page-29

Sheeees, Blokes and their tractors...what is it about big tyres that you find so attractive....

I didn't even know of this company as an ASX listed one until Roamin put it in the Tipping Comp, but after some initial searching I recognised their logo, long story. Grateful to Roamin for bringing it to my attention. I have spent most of Friday and Saturday researching and reading up on a range of related stuff and getting back up to speed on basic human genetics and I can't see anything about CYP not to like from a quick profit to a long profitable relationship, take your pick.

However I have just got home and read this thread with some amusement and dismay as it seems there are some close to the shares, some close to the company and then some that may or could have done with their product earlier. But I will make some observations given I am an amused observer and you may take them as you wish.
1. CYP share price? Plenty will tell you where it is going...all I can see is it seems to be highly desirable, reasonably tradable and highly investable for those with a longer horizon.
2. CYP has a rock solid governance and management team not only in the bio-research arena but, for investors alike, bringing it to market.
3. CYP has a rock solid platform (i.e. Cymerus - interesting play on the word "Chimaera" which is essentially genetic mutation) to produce "blank" cells (i.e cells that are yet to be assigned a specific function like bone, blood, organ tissue, skin, etc) from a manufactured process rather than a donor any time they are ready.
4. CYP might be running low on cash at this point so the focus will be partners. Possible capital raising or dilution from private placement or a new partnership arrangement.
5. CYP is a highly appealing company for potential investors of scale right now (i.e. the company will need to select very carefully the financial arrangements going forward as short term funding may compromise long term viability).
6. CYP has a differentiated product able to be scaled up with reasonable ease (I use this term a bit loosely)and delivered to an existing market (i.e. independence of continual seeking and sourcing live stem cells - grizzly topic).
7. CYP are about to enter into GVHD trials and this will further differentiated their product (i.e. any result better than a fail is an improvement on current treatments for GVHD as most treatment do not repatriate cells, they merely replace GVHD damaged cells on a continual basis or provide relief from the symptoms of GVHD so long as you stay on the treatment).
8. CYP have current R&D efforts in a number of streams for the same cell types (i.e. multiple product lines of differing "blank cells" for specific purposes or specific applications that could span a number of medical disciplines for anatomical replacement, reparation and recovery).
9. CYP it seems has only one possible peer of comparison (Kyoto University, Japan) but perhaps the current announcement puts them ahead, I don't know, but many competitors could suddenly become partners overnight (i.e. medical supply pharmaceuticals rather than retail pharmaceuticals).
10. A parallel company doing similar stem cell reparative work by using autologous treatment (i.e. good MSC cells from same individual virtually removing the risk of GVHD) for treating degenerative, aging or trauma damage, that company is ASX listed as RSG.AX (it might give some people a price guidance for guessing where CYP could go).
11. For sci-fi followers where you see near dead people bought back to life on the screen with an injection or some other fanciful transdermal "magic touch", well CYP could be the front end of this breakthrough technology even if a bit clunky like using an intraveneous or intrathecal pump or even a hickman line.
12. CYP is in the game of human genetics and modifying the human genome, for the better hopefully, but if this is a squeamish topic then best to either trade or just look at the share price.

I wish for CYP to come up with something readily available in the market that would reduce the patient impact for current stem cell therapy/treatment and then to grow this new platform into so many other areas of human physiological recovery from defects and trauma.

This sort of company is where the real world of human genetics touches the sci-fi world we saw in the movies less than 10 years ago. Incredible stuff.

Cheers.